Intercept’s OCA Facing Extended Approval Wait In NASH As Known Risks Swamp Uncertain Benefits

 
• By Sue Sutter
cloudy horizon
Panel vote suggests any approval of OCA for NASH will be far in the distance. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers